ES2575549T3 - Comprimido de melatonina y métodos de preparación y uso - Google Patents

Comprimido de melatonina y métodos de preparación y uso Download PDF

Info

Publication number
ES2575549T3
ES2575549T3 ES08742710.0T ES08742710T ES2575549T3 ES 2575549 T3 ES2575549 T3 ES 2575549T3 ES 08742710 T ES08742710 T ES 08742710T ES 2575549 T3 ES2575549 T3 ES 2575549T3
Authority
ES
Spain
Prior art keywords
melatonin
dissolved
dosage form
pharmaceutically acceptable
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08742710.0T
Other languages
English (en)
Inventor
John A. Mccarty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2575549T3 publication Critical patent/ES2575549T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una forma farmacéutica sólida para administración sublingual o bucal de una hormona que tiene de baja a escasa solubilidad acuosa, comprendiendo dicha forma farmacéutica melatonina en un estado disuelto, estando asociada dicha melatonina disuelta a un vehículo farmacéuticamente aceptable, en donde la melatonina está en un estado disuelto en la forma farmacéutica final, en donde la melatonina disuelta está adsorbida sobre dicho vehículo, en donde la melatonina se disuelve en un disolvente farmacéuticamente aceptable seleccionado de polietilenglicol, etanol, alcohol isopropílico, polietilenglicoles sustituidos, propilenglicol o una mezcla de los mismos y en donde el vehículo farmacéuticamente aceptable es sílice, en donde la forma farmacéutica sólida está en forma de un comprimido.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES08742710.0T 2007-04-11 2008-04-10 Comprimido de melatonina y métodos de preparación y uso Active ES2575549T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92292107P 2007-04-11 2007-04-11
US922921P 2007-04-11
PCT/US2008/004615 WO2008127609A1 (en) 2007-04-11 2008-04-10 Melatonin tablet and methods of preparation and use

Publications (1)

Publication Number Publication Date
ES2575549T3 true ES2575549T3 (es) 2016-06-29

Family

ID=39864239

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08742710.0T Active ES2575549T3 (es) 2007-04-11 2008-04-10 Comprimido de melatonina y métodos de preparación y uso

Country Status (11)

Country Link
US (3) US20100119601A1 (es)
EP (2) EP3056220A1 (es)
JP (2) JP5600058B2 (es)
CN (1) CN101677994B (es)
AU (1) AU2008239683B2 (es)
CA (1) CA2683436C (es)
ES (1) ES2575549T3 (es)
IL (2) IL201383A (es)
MX (1) MX2009010878A (es)
RU (1) RU2485949C2 (es)
WO (1) WO2008127609A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9254294B2 (en) 2003-02-24 2016-02-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
US9358296B2 (en) 2003-02-24 2016-06-07 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US10172810B2 (en) * 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
EP3056220A1 (en) * 2007-04-11 2016-08-17 John A. Mccarty Hormone tablet and metods of preparation
TR200907338A1 (tr) * 2009-09-28 2011-04-21 Yedi̇tepe Üni̇versi̇tesi̇ Doğal bileşenler içeren bir film şeridi.
CN103429223A (zh) * 2011-01-17 2013-12-04 武田药品工业株式会社 口腔分散片
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
EP2672981B1 (en) 2011-02-11 2018-03-28 Zx Pharma, Llc Multiparticulate l-menthol formulations and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
EP2570126B1 (en) 2011-09-16 2014-03-26 Darius Rassoulian Use of melatonin for treating acute alcohol intoxication
ITMI20112042A1 (it) * 2011-11-10 2013-05-11 Eratech S R L Polvere da ricostituire prima dell'uso comprendente melatonina e preparazione iniettabile ottenibile da tale polvere.
RU2488388C1 (ru) 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
CN113842362A (zh) 2012-11-14 2021-12-28 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
US20140303128A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
EP2988824B1 (en) 2013-04-23 2018-11-07 Zx Pharma, Llc Enteric coated multiparticulate composition with proteinaceous subcoat
AU2015292915B2 (en) * 2014-07-21 2020-10-15 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
CN105663061A (zh) * 2014-11-16 2016-06-15 刘佳迪 褪黑素滴丸的制法和用法
NL2015272B1 (en) * 2015-08-05 2017-05-02 Versailles B V Melatonin formulations and methods for preparation and use.
US20200030450A1 (en) * 2017-03-16 2020-01-30 Repoceuticals Aps Compositions for retarding the decomposition of melatonin in solution
US10806789B2 (en) * 2017-05-12 2020-10-20 The LIV Group Inc. Composition for enhanced absorption of supplements
MX2019015733A (es) 2017-06-20 2020-02-20 Physicians Seal Llc Formulacion de melatonina oralmente disoluble con agente acidificante que produce melatonina soluble en saliva.
WO2019038586A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited PHARMACEUTICAL COMPOSITION OF MELATONIN
CN109953953B (zh) * 2017-12-22 2021-09-21 深圳大学 一种褪黑素纳米缓释给药系统的制备方法
WO2019175100A1 (en) 2018-03-11 2019-09-19 Nanologica Ab Porous silica particles for use in compressed pharmaceutical dosage form
KR102506059B1 (ko) * 2020-10-20 2023-03-07 코스맥스 주식회사 멜라토닌을 포함하는 항산화용 화장료 조성물
CN112426408B (zh) * 2020-12-08 2023-12-19 广州帝奇医药技术有限公司 一种褪黑素组合物及其制备工艺
CN112870193B (zh) * 2021-03-11 2022-07-08 大连医科大学附属第二医院 褪黑素在制备治疗对靶向药物耐药的her2阳性乳腺癌的药物中的应用
WO2023210814A1 (ja) * 2022-04-28 2023-11-02 日本たばこ産業株式会社 無機多孔質材料を含む口腔用組成物
WO2023210811A1 (ja) * 2022-04-28 2023-11-02 日本たばこ産業株式会社 無機多孔質材料を含む口腔用組成物
WO2023210812A1 (ja) * 2022-04-28 2023-11-02 日本たばこ産業株式会社 多孔質材料を含む口腔用組成物
WO2023210813A1 (ja) * 2022-04-28 2023-11-02 日本たばこ産業株式会社 無機多孔質材料を含む口腔用組成物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US4945103A (en) * 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome
IT1243193B (it) 1990-08-10 1994-05-24 Medea Res Srl Composizioni farmaceutiche orali a base di melatonina
AU7550994A (en) 1993-07-26 1995-02-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Sustained release oral compositions containing melatonin
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
US5688520A (en) * 1995-03-29 1997-11-18 Minnesota Mining And Manufacturing Company Transmucosal delivery of melatonin for prevention of migraine
FR2742989B1 (fr) * 1995-12-29 1998-01-23 Adir Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs
BR9710289A (pt) * 1996-07-11 1999-08-17 Farmarc Nederland Bv Composi-Æo farmac-utica contendo sal cido de adi-Æo de medicamento b sico
US6620836B1 (en) * 1997-01-22 2003-09-16 Jay Patrick Antiarrhythmic and tranquilizer composition and treatment
CA2284719A1 (en) 1997-03-26 1998-10-01 Franciscus W.H.M. Merkus Nasal melatonin composition
FR2762513B1 (fr) * 1997-04-23 2003-08-22 Permatec Pharma Ag Comprimes bioadhesifs
IT1298731B1 (it) * 1998-03-13 2000-02-02 Recordati Chem Pharm Composizioni farmaceutiche contenenti complessi di inclusione con melatonina
JP4080686B2 (ja) * 2000-11-06 2008-04-23 株式会社リコー 画像形成装置
KR20010088917A (ko) * 2001-07-30 2001-09-29 최종욱 디지털 정보 보안 방법 및 그 시스템
IL164163A0 (en) * 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
CN1210026C (zh) * 2002-10-09 2005-07-13 重庆太极医药研究院 褪黑素双层控释片及制备工艺
JP5475215B2 (ja) * 2003-02-24 2014-04-16 ファーマシューティカル プロダクションズ， インコーポレイテッド 経粘膜薬物送達システム
WO2004096177A1 (de) * 2003-05-02 2004-11-11 Globopharm Pharmazeutische Produktions- Und Handelsgesellschaft M.B.H. Feste pharmazeutische zubereitung enthaltend levothyroxin- und/oder liothyroninsalze
JP2007508249A (ja) * 2003-10-10 2007-04-05 ライフサイクル ファーマ アクティーゼルスカブ フィブラートとスタチンを含む固体剤型
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
EP3056220A1 (en) * 2007-04-11 2016-08-17 John A. Mccarty Hormone tablet and metods of preparation
US20140303227A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system

Also Published As

Publication number Publication date
RU2485949C2 (ru) 2013-06-27
MX2009010878A (es) 2010-03-26
US20130028943A1 (en) 2013-01-31
CA2683436C (en) 2016-07-26
US20150174101A1 (en) 2015-06-25
US9381190B2 (en) 2016-07-05
EP3056220A1 (en) 2016-08-17
WO2008127609A1 (en) 2008-10-23
EP2144610A4 (en) 2013-08-07
IL249102A0 (en) 2017-01-31
JP5600058B2 (ja) 2014-10-01
RU2009137472A (ru) 2011-05-20
AU2008239683A1 (en) 2008-10-23
EP2144610A1 (en) 2010-01-20
EP2144610B1 (en) 2016-04-06
IL201383A0 (en) 2010-05-31
JP2014237700A (ja) 2014-12-18
US20100119601A1 (en) 2010-05-13
JP2010523673A (ja) 2010-07-15
US8992948B2 (en) 2015-03-31
IL201383A (en) 2017-01-31
AU2008239683B2 (en) 2014-03-27
CA2683436A1 (en) 2008-10-23
CN101677994A (zh) 2010-03-24
CN101677994B (zh) 2015-07-22

Similar Documents

Publication Publication Date Title
ES2575549T3 (es) Comprimido de melatonina y métodos de preparación y uso
ES2500068T3 (es) Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2629306T3 (es) Tratamiento y prevención de la mucositis mediante derivados de antocianidina
ES2551307T3 (es) Composición de inhalación que contiene aclidinio para tratamiento de enfermedad pulmonar obstructiva crónica
ES2563305T3 (es) Dispositivo de colágeno y procedimiento de preparación del mismo
CL2013003163A1 (es) Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion.
ES2575565T3 (es) Procedimiento para la preparación de monohidrato de treprostinilo y su utilización para el almacenamiento y el envío
ES2532948T3 (es) Composición tópica para el tratamiento de queratosis actínica
ES2550634T3 (es) Uso de nanocristales para un balón de suministro de fármaco
ES2478264T3 (es) Glicerosomas y uso de estos en preparaciones farmacéuticas y cosméticas para aplicación tópica
DOP2010000323A (es) Pirimidin-5-carboxamidas sustituidas 281
CO6351785A2 (es) Inhibidores de cinasa map p39
CR9626A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato
PA8842201A1 (es) Inhibidores macrocíclicos de serina proteasas de hepatitis c
CL2009000882A1 (es) Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer.
UY29701A1 (es) Formulaciones líquidas para la administración controlada de derivados de bencisoxazol
AR077629A1 (es) Mimetico de smac
AR033808A1 (es) Una composicion topica de anestesia local y los parches y los envases que la contienen
ECSP003847A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
ECSP099571A (es) Derivados pirazólicos como inhibidores de la 11-beta-hsd1
SV2008003106A (es) Composicion farmaceutica estable que contiene docetaxel y un metodo para fabricarla
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
AR068044A1 (es) Derivados de catecolamina y prodrogas de los mismos